Bylvay denied as not medically necessary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for bylvay are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied Bylvay for Medical Necessity

A medical-necessity denial from Blue Cross Blue Shield means the plan's clinical reviewer concluded that the submitted documentation did not demonstrate — to the plan's satisfaction — that Bylvay is the appropriate treatment for your specific diagnosis, disease severity, and treatment history. This is the most common denial type for specialty hepatology drugs and one of the most successfully appealed, because it turns entirely on the completeness and specificity of the clinical record submitted.

## Why It Is Appealable

BCBS's medical-necessity criteria must align with generally accepted clinical standards. If your chart documents the diagnosis, severity, and prior treatment course, and your prescriber can map each element of Bylvay's FDA-approved labeling criteria to a corresponding finding in the record, the denial standard is met. Federal protections apply:

• ACA §2719 / ERISA §503: Entitles you to a full and fair internal review and then independent external review.
• External review window: Generally four months from the final adverse decision — verify on your Explanation of Benefits.
• Expedited review: If your condition is urgent, an expedited decision (typically within 72 hours) is available.

## Appeal Process and Timeline

1. Request the complete denial letter including the specific criteria BCBS applied and the clinical rationale for the denial. 2. Request BCBS's current coverage/medical policy for Bylvay — this document lists exactly what must be demonstrated. 3. Have your prescriber prepare a detailed medical-necessity letter addressing each policy criterion with specific chart facts. 4. File the internal appeal within the deadline on your denial notice, attaching all supporting documentation. 5. Request external review if the internal appeal is denied.

## Documentation to Gather

• Diagnosis confirmation: Pathology, genetic testing, or specialist notes confirming the specific cholestatic liver disease and its subtype.
• Disease severity: Chart notes, recent laboratory trends, and imaging or biopsy findings documenting the clinical burden.
• Prior treatment history: A chronological list of every previously tried therapy, the duration of each trial, and documented outcomes (failure, adverse event, or intolerance).
• Prescriber medical-necessity letter: Must cite the FDA-approved prescribing information criteria and the BCBS policy criteria, then answer each one with the specific chart fact that satisfies it.
• Applicable guideline reference: Your prescriber should reference the relevant specialty-society guideline organization supporting Bylvay for this indication.

## Criteria-Mapping Structure

Obtain Bylvay's FDA-approved prescribing information from the manufacturer or the FDA website. Obtain BCBS's published coverage policy. For every stated requirement in both documents, record the exact chart finding (with date and source) that satisfies it. This matrix format is the most effective way to present a medical-necessity appeal.